A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. Beyond a visit to the Pharmalot ancestors, we plan to catch up on reading, chores, and naps. And what about you? This may be a good time to enjoy the great outdoors. You could plan a summer getaway. Or simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. And if this applies, remember to call Dad. See you soon …

After a prolonged row, the U.K.’s National Institute for Health and Care Excellence and Roche have finally struck a deal for routine use of the Kadcyla breast cancer drug on the National Health Service, The Guardian writes. Details were not disclosed, but Roche will offer a discount. Until now, the drug has only been covered by the Cancer Drugs Fund, which finances drugs not routinely paid for on the NHS.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X